| pubmed-article:2066970 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2066970 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2066970 | lifeskim:mentions | umls-concept:C0243038 | lld:lifeskim |
| pubmed-article:2066970 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:2066970 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:2066970 | lifeskim:mentions | umls-concept:C0887819 | lld:lifeskim |
| pubmed-article:2066970 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:2066970 | lifeskim:mentions | umls-concept:C1627358 | lld:lifeskim |
| pubmed-article:2066970 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:2066970 | pubmed:dateCreated | 1991-8-14 | lld:pubmed |
| pubmed-article:2066970 | pubmed:abstractText | Guanidinothiazolecarboxamides (GTCs) are a novel class of antitumor agents found to be systemically active against experimental pulmonary metastases of 3LL Lewis lung carcinoma. A series of substituted benzothiazole GTCs were found to produce enhancement of survival in this model by using 8 days of intraperitoneal dosing initiated 2 days after intravenous tumor challenge. Quantitative structure-activity relationships have been discovered in the GTC series with survival enhancement correlated to substituent parameters. Optimal correlations were found between the probit transform of the drug-induced increased lifespan (ILS) and field and pi parameters. Among the most effective analogues in this series was N-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxam ide. | lld:pubmed |
| pubmed-article:2066970 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2066970 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2066970 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2066970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2066970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2066970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2066970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2066970 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2066970 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:2066970 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:GoodwinPP | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:SloanD EDE | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:SingletonD... | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:SchnurR CRC | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:FliriA FAF | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:GrissomMM | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:GallaschunR... | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:McNiffP APA | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:ManganoF MFM | lld:pubmed |
| pubmed-article:2066970 | pubmed:author | pubmed-author:OlsonT HTH | lld:pubmed |
| pubmed-article:2066970 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2066970 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:2066970 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2066970 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2066970 | pubmed:pagination | 1975-82 | lld:pubmed |
| pubmed-article:2066970 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:meshHeading | pubmed-meshheading:2066970-... | lld:pubmed |
| pubmed-article:2066970 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:2066970 | pubmed:articleTitle | Quantitative structure-activity relationships of antitumor guanidinothiazolecarboxamides with survival enhancement for therapy in the 3LL Lewis lung carcinoma model. | lld:pubmed |
| pubmed-article:2066970 | pubmed:affiliation | Central Research, Pfizer Inc., Groton, Connecticut 06840. | lld:pubmed |
| pubmed-article:2066970 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:2066970 | lld:chembl |
